Halilbasic, Emina

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice†

Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 355

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 297

Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis

Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 275

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 227

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 169

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2−/− mice by modulating composition, signalling and excretion of faecal bile acids

Fuchs, C. D., Paumgartner, G., Mlitz, V., Kunczer, V., Halilbasic, E., Leditznig, N., Wahlström, A., Ståhlman, M., Thüringer, A., Kashofer, K., et al. (2018) · Gut

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 76

24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation

Zhu, C., Boucheron, N., Müller, A. C., Májek, P., Claudel, T., Halilbasic, E., Baazim, H., Lercher, A., Viczenczova, C., Hainberger, D., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 65

Nor-Ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases

Halilbasic, E., Steinacher, D., & Trauner, M. (2017) · Digestive Diseases

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 55

Fine‐Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease

Blokker, B. A., Maijo, M., Echeandia, M., Galduroz, M., Patterson, A. M., Ten, A., Philo, M., Schungel, R., Gutierrez‐de Juan, V., Halilbasic, E., et al. (2019) · Hepatology

Sirtuins and Resveratrol in MedicineLiver physiology and pathology

Cited by 46

Fibrate treatment for primary biliary cirrhosis

Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014) · Current Opinion in Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 36